Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 12, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…


Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…


Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

- Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio - Expands portfolio with PBGENE-PMM as a potentially…


Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 6, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies,…


Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 31, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will…


Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales - Imugene to Assume Control of Precision’s…


Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

- FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for…


Precision BioSciences to Report Second Quarter Results on August 4, 2023

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic…


Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic…


Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

- High antiviral activity with substantial and durable reductions in hepatitis B serum antigen and covalently closed circular DNA in preclinical studies of PBGENE-HBV - Supports continued PBGENE-HBV…


Precision BioSciences to Present at Upcoming June Investor Conferences

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 5, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based in vivo gene editing and ex vivo allogeneic…


Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T…


Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023

DURHAM, N.C. --(BUSINESS WIRE)--May 25, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR…


Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day

DURHAM, N.C. --(BUSINESS WIRE)--May 24, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR…


Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study DURHAM, N.C.…